🇺🇸 FDA
Patent

US 9687532

Sialylated glycoprotein compositons and uses thereof

granted A61KA61K38/47A61K45/06

Quick answer

US patent 9687532 (Sialylated glycoprotein compositons and uses thereof) held by Ultragenyx Pharmaceutical Inc. expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ultragenyx Pharmaceutical Inc.
Grant date
Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K38/47, A61K45/06, A61K9/0019, A61P